Omacor (Omega-3-Acid Ethyl Esters 90)

Omega-3-acid ethyl esters, the active ingredient in Omacor, is a prescription omega-3 fatty acid presented as a 90% ethyl ester concentration for oral use. It is indicated for the management of hyperlipidemia, particularly elevated triglyceride levels, in adult patients. GNH USA supplies Omacor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omacor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omacor is a prescription omega‑3 fatty acid that lowers elevated lipid levels through triglyceride reduction.

- Hypertriglyceridemia: reduces fasting triglyceride concentrations in patients with very high triglycerides. - Mixed dyslipidemia: helps lower triglycerides while modestly raising HDL‑cholesterol. - Cardiovascular risk reduction adjunct: used alongside statins to improve overall lipid profile in high‑risk patients. - Familial hypercholesterolemia adjunct: supports triglyceride control when combined with other lipid‑lowering therapies. - Post‑myocardial infarction care: part of a comprehensive lipid management strategy after an acute coronary event.

Omacor may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Fish‑like aftertaste or mild eructation. - Soft stools or mild diarrhea. - Elevated liver enzymes in a minority of patients. - Headache or transient dizziness.

Serious or Rare Side Effects: - Pancreatitis: acute inflammation of the pancreas. - Bleeding tendency: prolonged bleeding time or hemorrhagic events, especially with anticoagulants. - Severe allergic reactions: rash, pruritus, angio‑edema or anaphylaxis. - Atrial fibrillation: new‑onset or worsening arrhythmia. - Elevated serum creatinine: indicating possible renal impact. - Hyperglycaemia: significant rise in blood glucose levels.

When prescribing Omacor, clinicians should consider several safety aspects.

- Monitor triglyceride levels: assess response and adjust therapy as needed. - Assess liver function: baseline and periodic testing recommended. - Evaluate bleeding risk: caution in patients on anticoagulants or with coagulopathies. - Pregnancy and lactation: use only if clearly needed. - Renal function: adjust in severe renal impairment. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omacur may interact with several other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Warfarin and other vitamin K antagonists: may increase INR. - High‑dose fish‑oil supplements: additive effect on bleeding risk. - Orlistat: may reduce absorption of omega‑3 fatty acids.

Moderate Interactions (Monitor Closely): - Statins: monitor for muscle‑related symptoms. - Antihypertensive agents: potential additive blood‑pressure‑lowering effect. - Antidiabetic drugs: watch for changes in glycaemic control.